{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:35:04Z","timestamp":1781015704323,"version":"3.54.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.clgc.2016.12.020","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T02:46:32Z","timestamp":1482979592000},"page":"472-478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-9798","authenticated-orcid":false,"given":"Yasuhide","family":"Miyoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuko","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Teranishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Takebayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Yokomizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narihiko","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.12.020_bib1","first-page":"293","article-title":"Studies on prostatic cancer I: the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2016.12.020_bib2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/JCO.1997.15.1.382","article-title":"Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm","volume":"15","author":"Small","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.12.020_bib3","first-page":"1220","article-title":"Management of hormone refractory prostate cancer: current standards and future prospects","volume":"160","author":"Oh","year":"1998","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2016.12.020_bib4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.12.020_bib5","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.12.020_bib6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.12.020_bib7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.12.020_bib8","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.12.020_bib9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.12.020_bib10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2016.12.020_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.12.020_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.12.020_bib13","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.12.020_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13550-016-0173-z","article-title":"Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide","volume":"6","author":"Anand","year":"2016","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.clgc.2016.12.020_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/pros.23094","article-title":"Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation","volume":"76","author":"Badrising","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2016.12.020_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/pcan.2014.53","article-title":"Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and\/or docetaxel","volume":"18","author":"Cheng","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2016.12.020_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.05.005","article-title":"Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer","volume":"67","author":"Efstathiou","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.12.020_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.clgc.2016.03.021","article-title":"The effect of time to castration resistance on outcomes with abiraterone and enzalutamide in metastatic prostate cancer","volume":"14","author":"Hung","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2016.12.020_bib19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdv594","article-title":"A\u00a0prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel","volume":"27","author":"Chi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.12.020_bib20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/annonc\/mdv545","article-title":"Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials","volume":"27","author":"Fizazi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.12.020_bib21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.eururo.2016.02.055","article-title":"Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer","volume":"70","author":"Rescigno","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.12.020_bib22","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s12149-013-0749-x","article-title":"Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases","volume":"27","author":"Wakabayashi","year":"2013","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.clgc.2016.12.020_bib23","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.12.020_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2012.01.037","article-title":"A\u00a0novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index","volume":"62","author":"Ulmert","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.12.020_bib25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12149-014-0921-y","article-title":"Evaluation of a computer-assisted diagnosis system, BONENAVI version 2, for bone scintigraphy in cancer patients in a routine clinical setting","volume":"29","author":"Koizumi","year":"2015","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.clgc.2016.12.020_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y","article-title":"Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan","volume":"61","author":"Soloway","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.12.020_bib27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12885-015-1330-x","article-title":"Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer","volume":"15","author":"Miyoshi","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2016.12.020_bib28","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.urolonc.2014.08.006","article-title":"Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)","volume":"32","author":"Armstrong","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2016.12.020_bib29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2011.36.5791","article-title":"Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer","volume":"30","author":"Dennis","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.12.020_bib30","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s12149-012-0620-5","article-title":"Computer-aided diagnosis system for bone scintigrams from Japanese patients: importance of training database","volume":"26","author":"Horikoshi","year":"2012","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.clgc.2016.12.020_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2191-219X-3-9","article-title":"Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy","volume":"3","author":"Kaboteh","year":"2013","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.clgc.2016.12.020_bib32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/2191-219X-3-64","article-title":"Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index","volume":"3","author":"Kaboteh","year":"2013","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.clgc.2016.12.020_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2342-14-24","article-title":"Analysis of regional bone scan index measurements for the survival of patients with prostate cancer","volume":"14","author":"Kalderstam","year":"2014","journal-title":"BMC Med Imaging"},{"key":"10.1016\/j.clgc.2016.12.020_bib34","doi-asserted-by":"crossref","first-page":"E628","DOI":"10.1111\/j.1464-410X.2012.11355.x","article-title":"Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer","volume":"110","author":"Mitsui","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2016.12.020_bib35","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bju.13160","article-title":"Bone Scan Index predicts outcome in patients with metastatic hormone sensitive prostate cancer","volume":"117","author":"Poulsen","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2016.12.020_bib36","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","article-title":"A\u00a0contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis","volume":"13","author":"Armstrong","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.12.020_bib37","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1158\/1078-0432.CCR-05-0109","article-title":"Prostate cancer clinical trial end points: \u201cRECIST\u201ding a step backwards","volume":"11","author":"Scher","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.12.020_bib38","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316303664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316303664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:27:02Z","timestamp":1761564422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316303664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1558767316303664"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.12.020","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}